| Title |
The additional value of TGFβ1 and IL-7 to predict the course of prostate cancer progression
|
|---|---|
| Published in |
Cancer Immunology, Immunotherapy, November 2011
|
| DOI | 10.1007/s00262-011-1159-3 |
| Pubmed ID | |
| Authors |
Caroline Schroten, Natasja F. Dits, Ewout W. Steyerberg, Ries Kranse, Arno G. J. L. H. van Leenders, Chris H. Bangma, Robert Kraaij |
| Abstract |
Given the fact that prostate cancer incidence will increase in the coming years, new prognostic biomarkers are needed with regard to the biological aggressiveness of the prostate cancer diagnosed. Since cytokines have been associated with the biology of cancer and its prognosis, we determined whether transforming growth factor beta 1 (TGFβ1), interleukin-7 (IL-7) receptor and IL-7 levels add additional prognostic information with regard to prostate cancer-specific survival. |
Mendeley readers
The data shown below were compiled from readership statistics for 29 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 29 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Other | 7 | 24% |
| Student > Ph. D. Student | 5 | 17% |
| Researcher | 5 | 17% |
| Professor | 3 | 10% |
| Lecturer | 3 | 10% |
| Other | 4 | 14% |
| Unknown | 2 | 7% |
| Readers by discipline | Count | As % |
|---|---|---|
| Biochemistry, Genetics and Molecular Biology | 11 | 38% |
| Agricultural and Biological Sciences | 3 | 10% |
| Computer Science | 3 | 10% |
| Engineering | 3 | 10% |
| Medicine and Dentistry | 3 | 10% |
| Other | 3 | 10% |
| Unknown | 3 | 10% |
Attention Score in Context
This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 09 April 2020.
All research outputs
#7,450,670
of 22,778,347 outputs
Outputs from Cancer Immunology, Immunotherapy
#1,037
of 2,881 outputs
Outputs of similar age
#69,374
of 239,808 outputs
Outputs of similar age from Cancer Immunology, Immunotherapy
#17
of 40 outputs
Altmetric has tracked 22,778,347 research outputs across all sources so far. This one is in the 44th percentile – i.e., 44% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,881 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.2. This one is in the 37th percentile – i.e., 37% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 239,808 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 41st percentile – i.e., 41% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 40 others from the same source and published within six weeks on either side of this one. This one is in the 22nd percentile – i.e., 22% of its contemporaries scored the same or lower than it.